ImmuPharma plc (LON:IMM – Get Free Report) shares dropped 8.3% on Wednesday . The company traded as low as GBX 4.11 ($0.05) and last traded at GBX 4.59 ($0.06). Approximately 7,864,863 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 22,321,723 shares. The stock had previously closed at GBX 5 ($0.06).
ImmuPharma Trading Down 4.9 %
The company has a market capitalization of £17.87 million, a price-to-earnings ratio of -429.00 and a beta of 1.53. The business’s 50 day moving average price is GBX 2.34 and its two-hundred day moving average price is GBX 1.91.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Insider Buying Explained: What Investors Need to Know
- 3 Must-Have ETFs Set to Dominate This Quarter
- What Are Dividends? Buy the Best Dividend Stocks
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Where to Find Earnings Call Transcripts
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
